NORDETTE-21 (ethinyl estradiol; levonorgestrel) by Teva. Approved for pregnancy. First approved in 1982.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
NORDETTE-21 is an oral contraceptive tablet combining ethinyl estradiol and levonorgestrel, two synthetic hormones that prevent pregnancy by suppressing ovulation and altering cervical mucus. Approved in 1982, it remains a foundational hormonal contraceptive in the combined oral contraceptive (COC) class. The product operates as a fixed-dose, 21-day active tablet regimen followed by a 7-day hormone-free interval.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), the brand team likely focuses on generic defense and lifecycle extension rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Working on NORDETTE-21 offers limited growth potential but valuable experience in managing mature, generic-vulnerable products and defending market share in a crowded contraceptive landscape. This role is ideal for professionals skilled in payer negotiation, lifecycle extension strategy, and cost-efficient commercial operations rather than innovation or new indication development.
Worked on NORDETTE-21 at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.